Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.67 |
| ▸ | CDK8 | P49336 | 1/20 | 0.67 |
| ▸ | LDHA | P00338 | 2/20 | 0.48 |
| ▸ | LDHB | P07195 | 2/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 7/20 | 0.42 |
| ▸ | CDK9 | P50750 | 7/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 3/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15569612 | 1.00 | CCNC (0.67) | CCNCCDK8LDHALDHBCCNT1 | |
| SCHEMBL15569629 | 1.00 | CCNC (0.67) | CCNCCDK8LDHALDHBCCNT1 | |
| SCHEMBL5206319 | 0.82 | CCNC (0.72) | CCNCCDK8LDHALDHBCCNT1 | |
| SCHEMBL15569764 | 0.81 | XDH (0.47) | CCNCCDK8ADORA2AESR2CYP3A4 | |
| SCHEMBL15569765 | 0.81 | XDH (0.47) | CCNCCDK8ADORA2AESR2CYP3A4 | |
| SCHEMBL15570215 | 0.81 | XDH (0.47) | CCNCCDK8ADORA2AESR2CYP3A4 | |
| SCHEMBL15870486 | 0.81 | CCNC (1.00) | CCNCCDK8LDHALDHBCCNT1 | |
| SCHEMBL31624680 | 0.81 | XDH (0.47) | CCNCCDK8ADORA2AESR2CYP3A4 | |
| SCHEMBL15569663 | 0.80 | LDHA (0.57) | LDHALDHBCCNT1CDK9ADORA2A | |
| SCHEMBL15570343 | 0.80 | LDHA (0.57) | LDHALDHBCCNT1CDK9ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458106-B2 | Phenyl-pyridine/pyrazine amides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | claimed |
| EP-2888232-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2015-07-01 | — | — | EP | claimed |
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | claimed |
| WO-2014029726-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-27 | — | — | WO | claimed |
| US-9458106-B2 | Phenyl-pyridine/pyrazine amides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458106-B2 | Phenyl-pyridine/pyrazine amides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2016-10-04 | — | — | US | disclosed |
| EP-2888232-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2015-06-11 | — | — | US | disclosed |
| WO-2014029726-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2014-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158815-A1 | NOVEL PHENYL-PYRIDINE/PYRAZINE AMIDES FOR THE TREATMENT OF CANCER | TP53, RB1, HCCS | CCNC 127/4885CDK8 423/4885LDHA 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.